- Home
- ARCL vs KZIA Comparison
ARCL vs KZIA Comparison
Compare ARCL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$12.31
Company Overview
Basic Information| Metric | ARCL | KZIA |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.4M | 154.5M |
| IPO Year | 2025 | 2002 |
Fundamental Metrics
Financial Performance| Metric | ARCL | KZIA |
|---|---|---|
| Price | $10.01 | $12.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 14.3K | ★ 252.2K |
| Earning Date | N/A | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $4.86 |
| 52 Week High | $10.01 | $17.40 |
Technical Indicators
Market Signals| Indicator | ARCL | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 66.86 | 43.25 |
| Support Level | $9.88 | $11.39 |
| Resistance Level | $10.01 | $14.79 |
| Average True Range (ATR) | 0.02 | 1.22 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 90.00 | 1.75 |
Price Performance
Historical Comparison ARCL
KZIA
About ARCL ARC Group Acquisition I Corp Class A Ordinary Shares
ARC Group Acquisition I Corp is a blank check company.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.